BR112018001869A2 - método para preparação de ácidos biliares e derivados dos mesmos - Google Patents

método para preparação de ácidos biliares e derivados dos mesmos

Info

Publication number
BR112018001869A2
BR112018001869A2 BR112018001869A BR112018001869A BR112018001869A2 BR 112018001869 A2 BR112018001869 A2 BR 112018001869A2 BR 112018001869 A BR112018001869 A BR 112018001869A BR 112018001869 A BR112018001869 A BR 112018001869A BR 112018001869 A2 BR112018001869 A2 BR 112018001869A2
Authority
BR
Brazil
Prior art keywords
derivatives
preparation
bile acids
solvate
formula
Prior art date
Application number
BR112018001869A
Other languages
English (en)
Inventor
Gioiello Antimo
Pellicciari Roberto
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of BR112018001869A2 publication Critical patent/BR112018001869A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
    • C07J7/0035—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a hydroxy group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

a presente invenção refere-se a um método de preparação de compostos de fórmula (i) ou um sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável do mesmo, em que r1 é h, a-oh, ß-oh ou um grupo oxo.
BR112018001869A 2015-07-30 2016-07-22 método para preparação de ácidos biliares e derivados dos mesmos BR112018001869A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562198733P 2015-07-30 2015-07-30
PCT/US2016/043611 WO2017019524A1 (en) 2015-07-30 2016-07-22 Methods for preparation of bile acids and derivatives thereof

Publications (1)

Publication Number Publication Date
BR112018001869A2 true BR112018001869A2 (pt) 2018-09-18

Family

ID=57885146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001869A BR112018001869A2 (pt) 2015-07-30 2016-07-22 método para preparação de ácidos biliares e derivados dos mesmos

Country Status (15)

Country Link
US (1) US10414791B2 (pt)
EP (1) EP3328817A4 (pt)
JP (1) JP6830096B2 (pt)
KR (1) KR20180030204A (pt)
CN (1) CN108025994A (pt)
AR (1) AR105555A1 (pt)
AU (1) AU2016297821B2 (pt)
BR (1) BR112018001869A2 (pt)
CA (1) CA2993540A1 (pt)
IL (1) IL256971A (pt)
MA (1) MA43066A (pt)
MX (1) MX2018001145A (pt)
NZ (1) NZ739219A (pt)
TW (1) TW201710280A (pt)
WO (1) WO2017019524A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3305799A3 (en) * 2016-10-07 2018-06-20 Lupin Limited Salts of obeticholic acid
US11053275B2 (en) 2017-04-20 2021-07-06 Daewoong Bio Inc. Method for bile acid derivative by using continuous flow reaction
CN107200763B (zh) * 2017-06-01 2019-05-03 江苏佳尔科药业集团有限公司 一种以鹅去氧胆酸为原料合成石胆酸的方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111072744B (zh) * 2019-12-03 2021-09-14 江苏佳尔科药业集团股份有限公司 一种以ba为原料合成熊去氧胆酸的方法
WO2022039983A2 (en) * 2020-08-21 2022-02-24 Sandhill One, Llc Methods of making cholic acid derivatives and starting materials therefor
CN112220792A (zh) * 2020-09-30 2021-01-15 浙江大学 石胆酸用于制备缓解肝纤维化的药物中的应用
CA3235506A1 (en) * 2021-11-02 2023-05-11 Sandhill One, Llc High purity non-animal derived udca
CA3235515A1 (en) * 2021-11-02 2023-05-11 Sandhill One, Llc High purity non-animal derived tudca
CN114276397A (zh) * 2021-12-28 2022-04-05 湖北武当安泰药业有限公司 醋酸去氢表雄酮的制备方法
WO2023187398A1 (en) 2022-03-31 2023-10-05 NZP UK Limited 7-ketolithocholic acid for use in the treatment of gut dysbiosis and as a prebiotic

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360470A (en) * 1980-10-22 1982-11-23 Hoffmann-La Roche Inc. Process and intermediates for the synthesis of Vitamin D3 metabolites and chenodeoxycholic acid
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP2083621A4 (en) * 2006-11-20 2010-03-24 Satori Pharmaceuticals Inc MODULATORS OF AMYLOID BETA PRODUCTION
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
BRPI0813140C1 (pt) * 2007-06-19 2021-05-25 Kythera Biopharmaceuticals Inc método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário
US20130261317A1 (en) * 2010-09-27 2013-10-03 Kythera Biopharmaceuticals, Inc. Methods for preparing synthetic bile acids and compositions comprising the same
SI2753632T1 (sl) * 2011-09-08 2023-08-31 Sage Therapeutics, Inc. Nevroaktivni steroidi, njihovi sestavki in uporaba
CN102746356B (zh) * 2012-07-17 2014-03-05 湖北芳通药业股份有限公司 均相法生产醋酸去氢表雄酮的工艺方法
RU2021111681A (ru) 2013-03-13 2021-05-11 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их применение
CN103145784B (zh) 2013-03-25 2015-03-11 浙江仙琚制药股份有限公司 醋酸去氢表雄酮的制备方法
CN104045676A (zh) * 2013-12-13 2014-09-17 成都丽璟科技有限公司 一种生产双烯醇酮醋酸酯的方法

Also Published As

Publication number Publication date
WO2017019524A1 (en) 2017-02-02
EP3328817A1 (en) 2018-06-06
EP3328817A4 (en) 2019-04-03
AU2016297821B2 (en) 2020-03-12
US20190010184A1 (en) 2019-01-10
AU2016297821A1 (en) 2018-02-15
NZ739219A (en) 2019-03-29
KR20180030204A (ko) 2018-03-21
US10414791B2 (en) 2019-09-17
MX2018001145A (es) 2018-06-15
AR105555A1 (es) 2017-10-18
CA2993540A1 (en) 2017-02-02
TW201710280A (zh) 2017-03-16
IL256971A (en) 2018-03-29
JP6830096B2 (ja) 2021-02-17
JP2018523654A (ja) 2018-08-23
MA43066A (fr) 2018-06-06
CN108025994A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
BR112018001869A2 (pt) método para preparação de ácidos biliares e derivados dos mesmos
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
BR112018006892A2 (pt) moduladores do receptor farnesoide x
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
BR112018008936A2 (pt) métodos para a preparação de ácido obeticólico e derivados do mesmo
BR112017010893A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
BR112016028273A8 (pt) derivados radiorrotulados de composto de 2-amino6-fluoro-n-[5-fluoro-piridin-3-il]-pirazol[1,5-a]pirimidin3-carboxamida úteis como inibidor de atr cinase, processo para preparação do referido composto, bem como diferentes formas sólidas do mesmo, uso destas, e composição farmacêutica
BR122021005860A8 (pt) Derivados de aminoácidos e composição que os compreende
BR112017009657A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
BR112013020996A2 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
BRPI1014802B8 (pt) profármacos de triptolida.
BR112019003320A2 (pt) compostos de heteroaril carboxamida como inibidores de ripk2
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112021011325A2 (pt) Derivados de rapamicina
BR112018071441A2 (pt) métodos para a preparação de ácido obeticólico e derivados do mesmo
BR112018015018A2 (pt) derivado de amido azaciclo, método de preparação deste, e aplicação farmacêutica

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time